Media stories about Alexion Pharmaceuticals (NASDAQ:ALXN) have been trending positive on Saturday, according to Alpha One Sentiment. Alpha One, a subsidiary of Accern, rates the sentiment of press coverage by monitoring more than twenty million blog and news sources in real-time. Alpha One ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Alexion Pharmaceuticals earned a news impact score of 0.27 on Alpha One’s scale. Alpha One also assigned news stories about the biopharmaceutical company an impact score of 92 out of 100, indicating that recent press coverage is extremely likely to have an impact on the stock’s share price in the next several days.
Here are some of the news stories that may have effected Alpha One’s analysis:
- Cramer's lightning round: It's OK to own this stock — as long as you're diversified (finance.yahoo.com)
- Why Stay Bullish On Gilead (finance.yahoo.com)
- 5 Reasons Big Biotech Could Gain 25%-30% (finance.yahoo.com)
- Amgen, Gilead, Biogen Won't Lead The Biotech Boom — So Who Will? (finance.yahoo.com)
- Alexion’s (ALXN) Strensiq Results Positive in Long-Term Study (zacks.com)
Several research firms have recently weighed in on ALXN. Leerink Swann set a $208.00 price objective on Alexion Pharmaceuticals and gave the company a “buy” rating in a report on Monday, March 13th. JPMorgan Chase & Co. set a $170.00 price objective on Alexion Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, February 7th. Royal Bank of Canada reissued an “outperform” rating and issued a $177.00 price objective on shares of Alexion Pharmaceuticals in a report on Monday, March 27th. Zacks Investment Research raised Alexion Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, April 18th. Finally, Cowen and Company reaffirmed an “outperform” rating and set a $180.00 price target on shares of Alexion Pharmaceuticals in a report on Friday, April 28th. Seven research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the company. Alexion Pharmaceuticals has an average rating of “Buy” and an average price target of $168.10.
Shares of Alexion Pharmaceuticals (NASDAQ:ALXN) opened at 113.84 on Friday. The firm has a 50-day moving average price of $120.96 and a 200-day moving average price of $124.82. The firm has a market capitalization of $25.56 billion, a price-to-earnings ratio of 54.24 and a beta of 1.39. Alexion Pharmaceuticals has a 52 week low of $109.12 and a 52 week high of $157.02.
Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its quarterly earnings data on Thursday, April 27th. The biopharmaceutical company reported $1.38 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.05 by $0.33. The business had revenue of $870 million for the quarter, compared to the consensus estimate of $826.63 million. Alexion Pharmaceuticals had a return on equity of 10.58% and a net margin of 12.46%. The firm’s revenue was up 24.3% compared to the same quarter last year. During the same quarter last year, the business posted $1.11 EPS. On average, equities analysts expect that Alexion Pharmaceuticals will post $5.31 earnings per share for the current fiscal year.
In other Alexion Pharmaceuticals news, EVP John B. Moriarty sold 612 shares of Alexion Pharmaceuticals stock in a transaction dated Monday, February 27th. The stock was sold at an average price of $131.20, for a total value of $80,294.40. Following the sale, the executive vice president now owns 45,864 shares of the company’s stock, valued at approximately $6,017,356.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Edward Miller sold 260 shares of Alexion Pharmaceuticals stock in a transaction dated Monday, February 27th. The shares were sold at an average price of $131.20, for a total value of $34,112.00. Following the completion of the sale, the senior vice president now directly owns 15,214 shares in the company, valued at approximately $1,996,076.80. The disclosure for this sale can be found here. Insiders have sold a total of 11,476 shares of company stock worth $1,504,601 in the last ninety days. 4.41% of the stock is currently owned by company insiders.
WARNING: “Alexion Pharmaceuticals (ALXN) Receiving Positive News Coverage, Analysis Finds” was posted by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this report on another publication, it was illegally stolen and republished in violation of United States & international copyright law. The correct version of this report can be accessed at https://sportsperspectives.com/2017/05/20/alexion-pharmaceuticals-alxn-given-coverage-optimism-score-of-0-27-updated-updated.html.
Alexion Pharmaceuticals Company Profile
Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.